Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07570940 · ClinicalTrials.gov registry record · Phase 4

A Study Of Stellate Ganglion Blockade With Liposomal Bupivacaine In Preventing Atrial Fibrillation After Isolated Coronary Artery Bypass Grafting Surgery

A Phase 4 study, sponsored by Mayo Clinic.

Not yet
Registry status
Phase 4
Development phase
450
Enrollment target

NCT07570940: Clinical Trial Phase 4 study, sponsored by Mayo Clinic.

NCT07570940 is a Phase 4 study that has not yet begun recruiting, run by Mayo Clinic. The registered enrollment target is 450 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (13% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist → Add completion date to calendar (.ics) →

The verdict

NCT07570940, a Phase 4 study, has not yet begun recruiting, sponsored by Mayo Clinic.

NOT YET RECRUITING
Registry status
Phase 4
Development phase
450 participants
Enrollment target

Study Summary

The purpose of this study is assess the incidence of postoperative atrial fibrillation (POAF) within one week of surgery in patients who receive pre-surgical stellate ganglion blockade with liposomal bupivacaine, compared to those receiving a saline placebo, using continuous electrocardiographic monitoring via wearable ECG devices.

Primary Outcome

Total number of patients to experience postoperative atrial fibrillation within one week of CABG surgery.

Interventions

  • DRUG Placebo
  • DRUG Liposomal bupivacaine

Trial Details

FieldValue
Enrollment Target 450 participants
Start Date 2026-06
Est. Completion 2030-06
Phase Phase 4
Mayo Clinic

2,844 total trials

What is known before NCT07570940 opens enrollment

NCT07570940 is an interventional study that assigns participants to a tested intervention. The registered 450 participants enrollment target is mid-sized for trials with a published cap, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (13% lower).

The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.

NCT07570940 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT07570940 about?

NCT07570940 is a clinical study titled "A Study Of Stellate Ganglion Blockade With Liposomal Bupivacaine In Preventing Atrial Fibrillation After Isolated Coronary Artery Bypass Grafting Surgery". The purpose of this study is assess the incidence of postoperative atrial fibrillation (POAF) within one week of surgery in patients who receive pre-surgical stellate ganglion blockade with liposomal bupivacaine, compared to those receiving a saline placebo, using continuous electrocardiographic mon...

What is the current status of trial NCT07570940?

This trial is currently not yet recruiting. It is a Phase 4 study. The enrollment target is 450 participants. The study started on 2026-06. Estimated completion is 2030-06.

What interventions are being tested in trial NCT07570940?

The interventions under investigation include: Placebo (DRUG), Liposomal bupivacaine (DRUG).

Who is sponsoring clinical trial NCT07570940?

This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT07570940's enrollment target sits among peer trials

450 187th of 2000 higher than 1,813 of 2,000 other Phase 4 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00515060 · 450 participants

    Psychophysical Studies of Cancer Therapy Pain

  • NCT01257269 · 450 participants

    Genotype and Phenotype Correlation in Hereditary Thrombotic Thrombocytopenic Purpura (Upshaw-Schulman Syndrome)

  • NCT03047161 · 450 participants

    Electrophysiology of Fetal Arrhythmia

  • NCT03269630 · 450 participants

    New Orleans Pulmonary Hypertension Biobank

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT07570940, the US trial registry maintained by the National Library of Medicine. NCT07570940 (mid enrollment · none site footprint · not yet recruiting) retrieved and formatted by PlainTrial, see methodology.